FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1512-1513 June 1, 1995 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

A critical component of the development of drugs targeted at treating complex disorders is a reliable animal model that can predict efficacy in clinical trials. Until now, attempts to devise treatments for Alzheimer's disease have been hindered by the lack of such a model. A team of scientists has recently described a transgenic mouse¹ that may remedy this problem. The Athena mouse strain, termed PDAPP (platelet-derived growth factor promoter expressing amyloid precursor protein), has neuropathologic features characteristic of those observed in Alzheimer's disease. Specifically, these include amyloid plaques, dystrophic neurites, activated glia, and loss of synapses in the hippocampus and . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Walker, I. D (2000). Thrombophilia in pregnancy. J. Clin. Pathol. 53: 573-580 [Abstract] [Full Text]